We performed tissue analysis of serglycin expression in human low-grade (astrocytomas, oligoastrocytomas and oligodendrogliomas grade II, n = 87) and high-grade glioma (anaplastic gliomas and glioblastomas, n = 101) TMAs. The gene discussed is SRGN; the disease is central nervous system cancer.